| Exclusion Criteria: | 1) Patients who have received any prior treatment, other than initial debulking surgery, for the cancer being treated in this study.
2) Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, if it was completed >/= 3 years before registration in this study and if the patient remains free of recurrent or metastatic disease.
3) Patients with acute hepatitis or active infection requiring antibiotics.
4) Patients with active bleeding.
5) Patients with unstable angina or those who have had myocardial infarction within the past 6 months. Patients with evidence of cardiac conduction abnormalities (e.g., bundle branch block, heart block) are eligible if their cardiac status has been stable for the 6 months before study entry.
6) Patients whose circumstances at the time of entry onto the protocol would not permit completion of study or required follow-up.
7) Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and localized breast cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients may have received prior adjuvant chemotherapy for localized breast cancer if the therapy was completed >/= 3 years before registration in this study and if the patient remains free of recurrent or metastatic disease. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
8) Patients with synchronous primary endometrial cancer, or past history of endometrial cancer, are excluded, unless all of the following conditions are met: (1) Stage not greater than I-B; (2) Less than 3mm invasion without vascular or lymphatic invasion; (3) No poorly differentiated subtypes, including papillary serous, clear cell, or other FIGO Grade 3 lesions.
9) Patients with epithelial tumors of low malignant potential (borderline tumors). |